Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 17, Issue 1, 2007, Pages 76-82

  Naniwa, J ^a   Kigawa, J ^a   Kanamori, Y ^a   Itamochi, H ^a   Oishi, T ^a   Shimada, M ^a   Shimogai, R ^a   Kawaguchi, W ^a   Sato, S ^a   Terakawa, N ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Chemosensitivity test; Drug resistance genes; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; IRINOTECAN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOSENSITIVITY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETICS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; FEMALE; GENES, MDR; HUMANS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; RNA, MESSENGER;

EID: 33846827296     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00752.x     Document Type: Article

References (15)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
2. Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 2002;20:1161-63.
3. Sugiyama T, Yakushiji M, Nishida T et al. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 1998;128:211-8.
4. Kigawa J, Minagawa Y, Kanamori Y et al. Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer 1998;82:697-702.
5. Minagawa Y, Kigawa J, Irie T et al. Enhanced topoisomerase I activity and topoisomerase II content in cisplatin-resistant cancer cell lines. Jpn J Cancer Res 1997;88:1218-23.
6. Suda S, Akiyama S, Sekiguchi H, Kasai Y, Ito K, Nakao A. Evaluation of the histoculture drug response assay as a sensitivity test for anticancer agents. Surg Today 2002;32:477-81.
7. Kikuchi T, Daigo Y, Katagiri T et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192-205.
8. Kigawa J, Takahashi M, Minagawa Y et al. Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer. Int J Cancer 1999;84:521-4.
9. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992;89:3070-4.
10. Kamazawa S, Kigawa J, Kanamori Y et al. Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 2002;86:171-6.
11. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22:7537-52.
12. Yasui K, Mihara S, Zhao C et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 2004;64:1403-10.
13. Braybrooke JP, Levitt NC, Joel S et al. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIα expression. Clin Cancer Res 2003;9:4682-8.
14. Kigawa J, Minagawa Y, Cheng X, Terakawa N. Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 1998;4:1737-41.
15. Konecny G, Crohns C, Pegram M et al. Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000;77:258-63.